Patient-centric drug design to improve therapeutic outcomes

Published: 9-Feb-2017

Pharmaceutical companies put enormous amounts of time and money into developing drugs that are both safe and effective. Yet, all this effort comes to nothing if the patient fails to take the medication as instructed. Taking the patient’s view into consideration early on in the drug development process can greatly improve compliance rates, says Catalent

You need to be a subscriber to read this article.
Click here to find out more.

The leading cause of therapeutic failure in chronic conditions is patient non-compliance. The proportion of patients who fail to take their prescribed medications in accordance with instructions rises from nearly 40% after 6 months to almost 70% after a year.

The cost of non-adherence in North America alone was estimated to be $337 billion in 2013, so addressing the underlying issues that lead patients to give up on their medicines should be a priority.

There are several factors that affect patient compliance, including route of administration, pattern and frequency of dosing, length of treatment and drug side-effects.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like